CONTACT US
Press

Fast Company Names egnite, Inc. One of Its Most Innovative Companies in 2024

Fast Company Names egnite, Inc. One of Its Most Innovative Companies in 2024

ALISO VIEJO, Calif. – March 19, 2024 – Fast Company, the world’s leading progressive business media brand, announced egnite, Inc. as one of the World’s Most Innovative Companies in their 2024 ranking. egnite, a leading digital health company specializing in artificial intelligence solutions to advance cardiovascular care, stands at the forefront of innovation in the healthcare sector.

The 2024 list showcases businesses pioneering advancements within their industries, setting new standards for innovation and paving the way for future breakthroughs. Among these trailblazers, egnite is recognized for its significant contributions to improving healthcare efficiency and patient outcomes.

In a world where heart disease remains a leading cause of mortality, with over 800,000 annual deaths in the U.S. alone, egnite’s artificial intelligence (A.I.) solutions help physicians reduce variability in care to ensure patients get the right treatment at the right time. In 2023, the company launched several new artificial intelligence technologies focused on helping physicians identify patients with risk for stroke, heart failure, and heart valve disease. Today, clinicians use egnite’s technology to screen and monitor patients, ensuring significant disease is quickly detected and treated before it’s too late.

“Gaps in care may unintentionally delay care for patients with life-threatening cardiovascular diseases. Artificial Intelligence technologies hold the potential to dramatically improve patient care and alleviate burdens on healthcare providers nationwide. Through these innovative solutions, we’re enabling providers to practice top-of-license care and ensure more patients are receiving life-saving therapy,” says Kahla Verhoef, chief product officer of egnite.  

To date, egnite’s technology:

  • Helps providers save 2 lives a day
  • Improves workflow efficiencies by up to 55%.¹
  • Increased life-saving treatment rates by 25%²

egnite’s commitment to advancing healthcare through innovative technologies underscores its position as a leader in the digital health space. As the company continues to leverage its technology to help improve patient care, it remains dedicated to shaping the future of cardiovascular health.

About egnite, Inc.

egnite is a visionary digital health company committed to advancing the health of our society through innovative cardiovascular solutions. egnite uses AI-driven algorithms and big data to produce business intelligence for healthcare, elevating the role of data in critical decisions. The company, based in Aliso Viejo, California, partners with leading hospitals and life sciences organizations to transform care delivery for cardiovascular patients. For more information, visit www.egnitehealth.com.

References

  1. Compared to traditional screening methods
  2. Represents median growth from 17 CardioCare sites with baseline data one year after implementing the CardioCare platform.
Linkedin Twitter Youtube

Related Articles
Press

egnite’s Call for Science Study on M-TEER Device Durability and Long-Term Patient Outcomes to be Featured at TCT 2026

The egnite Registry contributed de-identified, longitudinal data, linking serial echocardiograms with clinical outcomes, to help answer what happens to patients after a successful mitral transcatheter edge-to-edge repair (M-TEER) procedure.  ALISO VIEJO, Calif. — October 13, 2026 — egnite, Inc., a cardiovascular intelligence company that helps clinicians identify and manage patients with untreated heart disease, today announced that Dr. John T. Saxon, Director of the Advanced Cardiac Valve Center at University of Virginia
Publications

Mitral Regurgitation and Severe Aortic Stenosis: Clinical Characteristics, Prognostic Impact, and Response to TAVR: Insights From egnite Data

BACKGROUND Aortic stenosis (AS) and mitral regurgitation (MR) frequently co-occur, complicating diagnosis and treatment. We examined current US treatment trends and patient outcomes among patients with severe AS and at least moderate MR. METHODS We analyzed data from 2 992 362 patients (aged ≥18 years) undergoing 5 245 904 echocardiograms at 43 US institutions

"The future of aortic stenosis care requires proactive identification, longitudinal monitoring, and intentional pipeline management."
egnite Research

Rethinking the Aortic Stenosis Pipeline

Aortic stenosis care is shifting from a reactive to a proactive model. Emerging clinical evidence supports earlier identification, closer monitoring, and intentional patient management across the disease continuum. As treatment thresholds evolve, health systems need scalable approaches to identify at-risk patients, close treatment gaps, and ensure timely access to specialist care.